{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:23:50Z","timestamp":1790889830298,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2984,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      <jats:bold>This study investigated the effects of rimonabant (SR141716), an antagonist of the cannabinoid receptor type 1 (CB1), on obesity-associated hepatic steatosis and related features of metabolic syndrome: inflammation (elevated plasma levels of tumor necrosis factor alpha [TNF\u03b1]), dyslipidemia, and reduced plasma levels of adiponectin. We report that oral treatment of obese (fa\/fa) rats with rimonabant (30 mg\/kg) daily for 8 weeks abolished hepatic steatosis. This treatment reduced hepatomegaly, reduced elevation of plasma levels of enzyme markers of hepatic damage (alanine aminotransferase, gamma glutamyltransferase, and alkaline phosphatase) and decreased the high level of local hepatic TNF\u03b1 currently associated with steatohepatitis. In parallel, treatment of obese (fa\/fa) rats with rimonabant reduced the high plasma level of the proinflammatory cytokine TNF\u03b1 and increased the reduced plasma level of the anti-inflammatory hormone adiponectin. Finally, rimonabant treatment also improved dyslipidemia by both decreasing plasma levels of triglycerides, free fatty acids, and total cholesterol and increasing the HDLc\/LDLc ratio. All the effects of rimonabant found in this study were not or only slightly observed in pair-fed obese animals, highlighting the additional beneficial effects of treatment with rimonabant compared to diet. These results demonstrate that rimonabant plays a hepatoprotective role and suggest that this CB1 receptor antagonist potentially has clinical applications in the treatment of obesity-associated liver diseases and related features of metabolic syndrome. (HEPATOLOGY 2007.)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.21641","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T18:16:26Z","timestamp":1180030586000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":265,"title":["Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa\/fa rats"],"prefix":"10.1097","volume":"46","author":[{"given":"Magali","family":"Gary-Bobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghizlane","family":"Elachouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Fran\u00e7ois","family":"Gallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Janiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ravinet-Trillou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Chabbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00ebl","family":"Cruccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pfersdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Arnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Croci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Soubri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Oury-Donat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Maffrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Scatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Lacheretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Le Fur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marc","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Bensaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20241201","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/13543776.10.6.819","article-title":"Patent focus on new antiobesity agents: September 1999February 2000.","volume":"10","author":"Carpino","year":"2000","journal-title":"Expert Opin Ther Patents"},{"key":"R2-17-20241201","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1079\/PNS200194","article-title":"Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ.","volume":"60","author":"Trayhurn","year":"2001","journal-title":"Proc Nutr Soc"},{"key":"R3-17-20241201","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1079\/BJN20041213","article-title":"Adipokines: inflammation and the pleiotropic role of white adipose tissue.","volume":"92","author":"Trayhurn","year":"2004","journal-title":"Br J Nutr"},{"key":"R4-17-20241201","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.beem.2005.07.001","article-title":"White adipose tissue and cardiovascular disease.","volume":"4","author":"Matsuzawa","year":"2005","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R5-17-20241201","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1210\/en.2003-0580","article-title":"Minireview: the adipocyteat the crossroads of energy homeostasis, inflammation, and atherosclerosis.","volume":"144","author":"Rajala","year":"2003","journal-title":"Endocrinology"},{"key":"R6-17-20241201","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1385\/ENDO:23:2-3:177","article-title":"The role of TNF alpha in insulin resistance.","volume":"23","author":"Borst","year":"2004","journal-title":"Endocrine"},{"key":"R7-17-20241201","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/oby.2004.24","article-title":"A novel pathway to the manifestations of metabolic syndrome.","volume":"12","author":"Sonnenberg","year":"2004","journal-title":"Obes Res"},{"key":"R8-17-20241201","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1172\/JCI117936","article-title":"Increased adipose tissue expression of tumor necrosis factoralpha in human obesity and insulin resistance.","volume":"95","author":"Hotamisligil","year":"1995","journal-title":"J Clin Invest"},{"key":"R9-17-20241201","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3349\/ymj.2005.46.4.449","article-title":"Obesity, insulin resistance and cancer risk.","volume":"46","author":"Jee","year":"2005","journal-title":"Yonsei Med J"},{"key":"R10-17-20241201","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1161\/01.ATV.0000116217.57583.6e","article-title":"Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.","volume":"24","author":"Den Boer","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R11-17-20241201","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.293.4.455","article-title":"Obesity, weight gain, and the risk of kidney stones.","volume":"293","author":"Taylor","year":"2005","journal-title":"JAMA"},{"key":"R12-17-20241201","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1210\/jc.2004-0372","article-title":"Obesity, metabolic syndrome, and cardiovascular disease.","volume":"89","author":"Grundy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-17-20241201","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11892-005-0071-7","article-title":"The evolving role of inflammation in obesity and the metabolic syndrome.","volume":"5","author":"Lee","year":"2005","journal-title":"Curr Diab Rep"},{"key":"R14-17-20241201","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI200319451","article-title":"Chronic inflammation in fat plays a crucial role in the development of obesity related insulin resistance.","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"R15-17-20241201","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/jama.291.14.1730","article-title":"Plasma adiponectin levels and risk of myocardial infarction in men.","volume":"291","author":"Pischon","year":"2004","journal-title":"JAMA"},{"key":"R16-17-20241201","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1253\/circj.68.975","article-title":"Adiponectin as a biomarker of the metabolic syndrome.","volume":"68","author":"Ryo","year":"2004","journal-title":"Circ J"},{"key":"R17-17-20241201","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/14779072.3.3.465","article-title":"Adiponectin: linking the metabolic syndrom to its cardiovascular consequences.","volume":"3","author":"Rabin","year":"2005","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R18-17-20241201","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gut.2003.024935","article-title":"Cytokines and the pathogenesis of nonalcoholic steatohepatitis.","volume":"54","author":"Diehl","year":"2005","journal-title":"Gut"},{"key":"R19-17-20241201","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1517\/14728214.10.3.661","article-title":"Nonalcoholic fatty liver disease: a review.","volume":"10","author":"Poordad","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"R20-17-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI200317797","article-title":"The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"R21-17-20241201","doi-asserted-by":"crossref","first-page":"123","DOI":"10.33549\/physiolres.930479","article-title":"Adiponectin and its role in the obesityinduced insulin resistance and related complications.","volume":"53","author":"Haluzik","year":"2004","journal-title":"Physiol Res"},{"key":"R22-17-20241201","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1530\/eje.1.01821","article-title":"Plasma adiponectin is decreased in nonalcoholic fatty liver disease.","volume":"152","author":"Pagano","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"R23-17-20241201","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3748\/wjg.v11.i12.1737","article-title":"Adiponectin as a protective factor in hepatic steatosis.","volume":"11","author":"MendezSanchez","year":"2005","journal-title":"World J Gastroenterol"},{"key":"R24-17-20241201","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1210\/er.2005-0005","article-title":"Adiponectin and adiponectin receptors.","volume":"26","author":"Kadowaki","year":"2005","journal-title":"Endocr Rev"},{"key":"R25-17-20241201","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.bjc.6603051","article-title":"Adiponectin and cancer: a systematic review.","volume":"94","author":"Kelesidis","year":"2006","journal-title":"Br J Cancer"},{"key":"R26-17-20241201","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1210\/jcem.87.6.8550","article-title":"Decreased plasma adiponectin concentrations in women with dyslipidemia.","volume":"87","author":"Matsubara","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-17-20241201","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1161\/01.CIR.0000042707.50032.19","article-title":"Adiponectin reduces atherosclerosis in apolipoprotein Edeficient mice.","volume":"106","author":"Okamoto","year":"2002","journal-title":"Circulation"},{"key":"R28-17-20241201","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1210\/jc.2004-0518","article-title":"Adiponectin: a novel adipokine linking adipocytes and vascular function.","volume":"89","author":"Goldstein","year":"2004","journal-title":"Clin Endocrinol Metab"},{"key":"R29-17-20241201","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.dld.2003.12.008","article-title":"Nonalcoholic fatty liver and insulin resistance: a causeeffect relationship?","volume":"36","author":"Bugianesi","year":"2004","journal-title":"Dig Liver Dis"},{"key":"R30-17-20241201","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ajcn\/79.3.502","article-title":"Model of nonalcoholic steatohepatitis.","volume":"79","author":"Lieber","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"R31-17-20241201","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gut.2005.071118","article-title":"Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of nonalcoholic steatohepatitis in mice.","volume":"55","author":"Tomita","year":"2006","journal-title":"Gut"},{"key":"R32-17-20241201","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM200011163432007","article-title":"Cytokines in alcoholic and nonalcoholic steatohepatitis.","volume":"343","author":"Tilg","year":"2000","journal-title":"N Engl J Med"},{"key":"R33-17-20241201","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s002130050326","article-title":"Selective inhibition of sucrose and ethanol intake by SR 141716 an antagonist of central cannabinoid (CB1) receptors.","volume":"132","author":"Arnone","year":"1997","journal-title":"Psychopharmacology"},{"key":"R34-17-20241201","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s002130050518","article-title":"Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats.","volume":"135","author":"Chaperon","year":"1998","journal-title":"Psychopharmacology"},{"key":"R35-17-20241201","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0024-3205(98)00322-1","article-title":"Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.","volume":"63","author":"Colombo","year":"1998","journal-title":"Life Sci"},{"key":"R36-17-20241201","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","article-title":"Leptinregulated endocannabinoids are involved in maintaining food intake.","volume":"410","author":"Di Marzo","year":"2001","journal-title":"Nature"},{"key":"R37-17-20241201","doi-asserted-by":"crossref","first-page":"R345","DOI":"10.1152\/ajpregu.00545.2002","article-title":"Antiobesity effect of SR141716, a CB1 receptor antagonist, in dietinduced obese mice.","volume":"284","author":"RavinetTrillou","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R38-17-20241201","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.63.4.908","article-title":"The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fafa rats and in cultured adipocyte cells.","volume":"63","author":"Bensaid","year":"2003","journal-title":"Mol Pharmacol"},{"key":"R39-17-20241201","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2004.00374.x","article-title":"The antiobesity effect of rimonabant is associated with an improved serum lipid profile.","volume":"7","author":"Poirier","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"R40-17-20241201","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1year experience from the RIOEurope study.","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"R41-17-20241201","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Rimonabant in ObesityLipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"key":"R42-17-20241201","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIONorth America: a randomized controlled trial.","volume":"295","author":"PiSunyer","year":"2006","journal-title":"JAMA"},{"key":"R43-17-20241201","doi-asserted-by":"crossref","first-page":"35i","DOI":"10.1016\/S0002-9149(03)00507-1","article-title":"Diagnosis, prevention, and intervention for the metabolic syndrome.","volume":"92","author":"Scott","year":"2003","journal-title":"Am J Cardiol"},{"key":"R44-17-20241201","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.it.2003.10.013","article-title":"Inflammation: the link between insulin resistance, obesity and diabetes.","volume":"25","author":"Dandona","year":"2004","journal-title":"Trends Immunol"},{"key":"R45-17-20241201","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/mol.105.015040","article-title":"The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.","volume":"69","author":"GaryBobo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"R46-17-20241201","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11892-005-0071-7","article-title":"The evolving role of inflammation in obesity and the metabolic syndrome.","volume":"5","author":"Lee","year":"2005","journal-title":"Curr Diab Rep"},{"key":"R47-17-20241201","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to dietinduced obesity.","volume":"115","author":"OseiHyiaman","year":"2005","journal-title":"J Clin Invest"},{"key":"R48-17-20241201","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/07853890510037419","article-title":"The endocannabinoid system and the treatment of obesity.","volume":"37","author":"Pagotto","year":"2005","journal-title":"Ann Med"},{"key":"R50-17-20241201","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00000441-200512000-00007","article-title":"Importance and management of dyslipidemia in the metabolic syndrome.","volume":"330","author":"Menuet","year":"2005","journal-title":"Am J Med Sci"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21641","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200707000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T08:08:40Z","timestamp":1733040520000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200707000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21641","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1090070.543273","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}